News
FDA could make it harder to get young kids a COVID shot
The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy children younger than 5 years old, a move that would add another barrier for parents who want to vaccinate healthy children ahead of the respiratory virus season.
Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...
Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...
Dealbreaker on MSN3d
BioNTech to Pay $740M-Plus to Settle mRNA Patent Disputes, Smooth $1.25 Billion Deal
In litigation over the past two years, CureVac alleged the BioNTech and Pfizer vaccine for Covid-19 infringed CureVac patents based on its more than two decades of mRNA research. Under terms of the ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
The Manila Times on MSN12d
Pfizer and BioNTech lose UK court appeal over Covid-19 jab
Pfizer says it will appeal the Aug 1 ruling to Britain’s Supreme Court. Read more at straitstimes.com. Read more at ...
Pfizer (PFE -1.64%) and BioNTech (BNTX -1.15%) recently fell behind in their race with Moderna (MRNA -1.60%) to develop new combination shots that could be worth billions in annual sales.
The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback